INSM - Insmed Incorporated
After hours:
| Previous Close | 18.70 |
| Open | 18.70 |
| Bid | 18.07 x 800 |
| Ask | 19.58 x 800 |
| Day's Range | 18.59 - 19.01 |
| 52 Week Range | 16.04 - 28.94 |
| Volume | |
| Avg. Volume | 1,130,914 |
| Market Cap | 2.564B |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.30 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.42 |
ZacksInsmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -8.33% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksRevance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksInsmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Insmed Incorporated's (NASDAQ:INSM) Business Is Trailing The Industry But Its Shares Aren't
There wouldn't be many who think Insmed Incorporated's ( NASDAQ:INSM ) price-to-sales (or "P/S") ratio of 9.9x is worth...
- Simply Wall St.
A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Insmed fair value estimate is US$17.70 Current share price of...
- Simply Wall St.
Insmed Full Year 2022 Earnings: EPS Misses Expectations
Insmed ( NASDAQ:INSM ) Full Year 2022 Results Key Financial Results Revenue: US$245.4m (up 30% from FY 2021). Net loss...
ZacksInsmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Insiders of Insmed Incorporated (NASDAQ:INSM) are up 17% on their US$1.7m purchase after Insmed Incorporated (NASDAQ:INSM) rose 5.0% last week
Insmed Incorporated ( NASDAQ:INSM ) insiders who bought shares over the past year were rewarded handsomely last week...
ZacksY-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Y-mAbs Therapeutics, Inc. (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireAnalysts and Executives Converge February 2nd at the 30th Annual Emerald Groundhog Day Investment Forum
LANCASTER, Pa., January 26, 2023--Emerald Advisers celebrated 30 years managing client funds in 2022 and is presenting the 30th Annual Groundhog Day Investment Forum on February 2nd.
ZacksWall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade
The mean of analysts' price targets for Insmed (INSM) points to a 98.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Simply Wall St.
The past five years for Insmed (NASDAQ:INSM) investors has not been profitable
The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have...
- Zacks
Insmed (INSM) Reports Q3 Loss, Misses Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -22.47% and 0.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksVoyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy?
Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWill Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Insmed's Shares Fell 14.7% on Wednesday
The biotech company is raising money to help it launch another drug, but it's diluting current shareholders in the process.
- Zacks
Insmed (INSM) Upgraded to Buy: What Does It Mean for the Stock?
Insmed (INSM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ZacksBluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?
Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Are Investors Undervaluing Insmed Incorporated (NASDAQ:INSM) By 47%?
Does the September share price for Insmed Incorporated ( NASDAQ:INSM ) reflect what it's really worth? Today, we will...
- Simply Wall St.
Investors bid Insmed (NASDAQ:INSM) up US$686m despite increasing losses YoY, taking five-year CAGR to 19%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
ZacksInsmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksEarnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.